BIOLASE Announces Agreement With the University of Florida College of Dentistry

BIOLASE Technology, Inc. (NASDAQ: BLTI), a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine, announced today that the Company has recently signed an agreement with the University of Florida College of Dentistry to integrate Waterlase dentistry into its course curriculum. The signing of the agreement marks another important milestone in the Company's strategy to work closely with leading dental schools to expand the application of Waterlase dentistry through teaching and research programs.

"We are pleased to be one of the first institutions to participate in the launch of the BIOLASE University Program. Our faculty is very excited to gain hands-on experience with the Waterlase technology, and we anticipate advancing its use through clinical research and incorporating, where appropriate, content into the various curricula in the college," said Teresa A. Dolan, professor and dean of the University of Florida College of Dentistry.

"The department of pediatric dentistry is very excited to have this opportunity to implement laser technology in its pediatric dentistry curriculum. The first phase of this implementation will consist of the development of laboratory research projects we hope will lead to clinical trials assessing the use of laser dentistry in children," commented Marcio Guelmann, professor and chair of pediatric dentistry at the University of Florida College of Dentistry.

"I believe laser technology is on a path to be a main stream dental tool in every dental practice. This technology offers many and significant advantages over how we practice dentistry today. I also believe dental lasers will continue to evolve and will eventually change how we practice dentistry in the future. We feel obligated to study this technology with the goal of incorporating it into our curriculum for the sake of our patients, students and the advancement of our profession," commented Amer Abu-Hanna, assistant professor of operative dentistry at the University of Florida College of Dentistry.

The University of Florida College of Dentistry is one of the top dental schools in the nation with recognized strengths in teaching, research and service. The college was founded in 1972 and has graduated more than 2,000 dentists. With 16 accredited programs, the college is the only publicly funded dental school in the State of Florida and enjoys a growing national reputation for its oral health research enterprise, emphasizing infectious diseases in dentistry, bone biology, pain and neurosciences and practiced based studies to improve clinical dental care. The college was recently ranked No. 4 out of 56 U.S. dental schools in terms of federal research funding.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. ( http://www.biolase.com ) is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine. The Company's products incorporate patented and patent pending technologies focused on reducing pain and improving clinical results. Its primary product, the Waterlase® system, is one of the best selling dental laser systems. The Waterlase system uses a patented combination of water and laser to precisely cut hard tissue, such as bone and teeth, and soft tissue, such as gums, with minimal or no damage to surrounding tissue. The Company also offers the LaserSmile(TM) system, which uses a laser to perform soft tissue and cosmetic procedures, including tooth whitening. The Company is also developing a laser for use in the field of ophthalmology.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

For further information, please contact: Jeffrey W. Jones President & CEO Richard L. Harrison Executive Vice President and CFO Scott Jorgensen Vice President - Business Development BIOLASE Technology, Inc. 1-949-361-1200